Relmada Therapeutics, Inc. (RLMD)
4.31
-0.12
(-2.71%)
USD |
NASDAQ |
Jan 09, 16:00
4.30
-0.01
(-0.23%)
After-Hours: 20:00
Relmada Therapeutics Research and Development Expense (Annual): 46.18M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Amicus Therapeutics, Inc. | 109.36M |
| Invivyd, Inc. | 137.25M |
| Arcellx, Inc. | 157.09M |
| Puma Biotechnology, Inc. | 54.94M |
| NovaBay Pharmaceuticals, Inc. | 0.042M |